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ABSTRACT: A point-of-care blood test for the detection of an
emerging biomarker, CCL17/TARC, could prove transformative
for the clinical management of classic Hodgkin lymphoma (cHL).
Primary care diagnosis is challenging due to nonspecific clinical
presentation and lack of a diagnostic test, leading to significant
diagnostic delays. Treatment monitoring encounters false-positive
and negative results, leading to avoidable chemotherapy toxicity, or
undertreatment, impacting patient morbidity and mortality. Here,
we present an amperometric CCL17/TARC immunosensor, based
on the utilization of a thiolated heterobifunctional cross-linker and
sandwich antibody assay, to facilitate novel primary care triage and
chemotherapy monitoring strategies for cHL. The immunosensor
shows excellent analytical performance for clinical testing; linearity
(R2 = 0.986), detection limit (194 pg/mL), and lower and upper limits of quantitation (387−50 000 pg/mL). The biosensor
differentiated all 42 newly diagnosed cHL patients from healthy volunteers, based on serum CCL17/TARC concentration, using
blood samples collected prior to treatment intervention. The immunosensor also discriminated between paired blood samples of all
seven cHL patients, respectively, collected prior to treatment and during chemotherapy, attributed to the decrease in serum CCL17/
TARC concentration following chemotherapy response. Overall, we have shown, for the first time, the potential of an
electrochemical CCL17/TARC biosensor for primary care triage and chemotherapy monitoring for cHL, which would have positive
clinical and psychosocial implications for patients, while streamlining current healthcare pathways.
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An electrochemical CCL17/TARC immunosensor forprimary care triage and secondary care chemotherapy
monitoring would represent a paradigm shift in the clinical
management of classic Hodgkin lymphoma (cHL). Recently,
the chemokine, CCL17/TARC, has emerged as a highly
promising candidate blood biomarker for cHL, which could be
utilized for early diagnosis, monitoring treatment response, and
early detection of relapse. Presently, no point-of-care blood
tests exist for cHL in primary or secondary care. A primary care
CCL17/TARC test would promote early detection of difficult
to diagnose adolescent and young adult patients, enabling
timely secondary care referral and accelerated diagnosis with
core or excision biopsy. A CCL17/TARC test in oncology and
hematology clinics would permit blood-based treatment
response monitoring, enabling next-day clinical decisions
prior to chemotherapy cycles.
cHL is a B-cell-derived malignancy characterized by
Hodgkin and Reed-Sternberg cells, the tumor cells, in a
background of inflammatory cells. The interaction between
Hodgkin and Reed-Sternberg cells and inflammatory cells is
crucial to cHL pathogenesis. CCL17/TARC is highly ex-
pressed by Hodgkin and Reed-Sternberg cells and most likely
plays a role in attracting T helper 2 (Th2) cells into the tumor
microenvironment.1,2 CCL17/TARC is elevated in ≥90% of
untreated cHL patient serum samples relative to healthy
persons,3,4 and correlates with tumor burden,4−6 and Ann
Arbor stage.3,5,7,8 Moreover, CCL17/TARC falls rapidly in
response to successful treatment.4
In the United Kingdom (U.K.), ∼2100 individuals are
diagnosed with Hodgkin lymphoma (HL) per year,9 which
represents ∼10% of all lymphoma cancers,10−12 and >90% of
these are cHL.11,13 cHL has a bimodal age-specific incidence
curve with one peak for young adult (15−34 years) and elderly
(≥50 years) patient groups, respectively. In industrialized
countries, cHL is the commonest malignancy in persons aged
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15−24 years. Patients often present with painless cervical
lymphadenopathy, symptoms related to enlarged mediastinal
nodes, such as dry cough or shortness of breath,11,12,14 or
systemic symptoms such as fever, night sweats, and weight loss
(B symptoms). Itchy skin and alcohol-induced lymph node
pain may also be present.14−16
Nonspecific clinical presentation and lack of a diagnostic test
cause diagnostic delays. Timely diagnosis is a particular
challenge in patients <40 years of age; only 0.4% of patients
who present to primary care with lymphadenopathy will have
cancer.17 National Institute for Health and Care Excellence
(NICE) guidelines recommend referral of symptomatic
patients through the “two-week wait” cancer pathway;18
however, only one-third access diagnosis through this pathway,
while almost one-fifth access emergency settings.19,20 Patients
diagnosed in emergency settings are more likely to have an
advanced-stage disease, with poorer 3 year relative survival
compared to patients diagnosed through nonemergency
routes.19 Delayed diagnosis has negative psychosocial effects
for patients and families; these data further suggest that
delayed diagnosis leads to inferior clinical outcomes. Hence,
there is a strong argument for primary care triage to accelerate
patient referral.
cHL has a good prognosis with cure rates of >90% in
patients with the limited-stage disease and ∼70% in patients
with advanced-stage disease.21 Treatment aims to cure cHL
while minimizing side effects, which cause significant patient
morbidity and mortality, since most are young at diagnosis.21
Treatment protocols now incorporate response-adapted
therapy where interim fluorodeoxyglucose (18F) positron
emission tomography, coupled with computerized tomography
(PET-CT), is used to assess treatment response after two or
three chemotherapy cycles to guide treatment decisions.
Although PET-CT has improved outcomes, it is not perfect.22
False-positive results lead to avoidable, delayed toxicity,8,23,24
and false-negative results lead to undertreatment and
disappointing outcomes.8 Hence, more sensitive markers are
needed to evaluate therapeutic response.22 Pretreatment
CCL17/TARC falls rapidly with successful treatment response,
and interim CCL17/TARC may better assess monitoring
compared to PET/CT.5,25 CCL17/TARC may inform treat-
ment response after one cycle of chemotherapy,5,25 allowing
earlier identification of refractory patients compared to PET-
CT. Hence, a CCL17/TARC test may be useful as an adjunct
or alternative to PET-CT to improve risk-adapted therapy.
Electrochemical immunosensors permit characterization of
antibody−antigen interactions into quantifiable electrical
signals. The technology has the potential to provide rapid,
economical point-of-care clinical testing.26,27 Thus far, diverse
approaches have been reported for electrochemical biomarker
detection, outlined in review articles.28−32 Previously, we
developed an “unlabeled” electrochemical immunosensor for
TREM-1, MMP-9, HSL, and IL-6 biomarkers.33 However,
sandwich-based “labeled” strategies improve assay sensitivity
and reproducibility for clinical testing, by overcoming
nonspecific adsorption of biomolecules.26 Sandwich-based
electrochemical biosensors have demonstrated the detection
of cancer biomarkers, such as prostate-specific antigen,34 α-
fetoprotein,35 CA19-9,36 HER2,37 and CEA.38 Recently, micro-
and nanotechnology and sophisticated surface chemistries have
increasingly been utilized to improve test performance. The
Estrela group reported an electrochemical biosensor that
utilized carboxylic functionalized popypyrrole films of nano-
meter thickness on microarray electrodes for blood testing.39
The Ingber group developed an antifouling coating, which
featured a network of nanomaterials, to reduce nonspecific
adsorption of biomolecules for anti-interleukin 6 detection in
blood.40 The Morgan group also demonstrated a fully
integrated microfluidic electrochemical system for blood
cytokine detection.41 Critically, however, clinical acceptance
and adoption of electrochemical biosensors for clinical testing
remain elusive, particularly for cancer diagnostics.
Principally, there is an urgent need to translate proof-of-
principle studies on spiked samples,34,35,37,38 into clinical
feasibility studies with cancer patients to validate performance.
Proposed electrochemical strategies must also be conducive to
Figure 1. Product concept for the proposed electrochemical sensor and overview of the developed sandwich immunoassay.
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commercialization to promote clinical adoption and minimize
costs per test for healthcare. Thus, we propose robust clinical
testing of an electrochemical CCL17/TARC sandwich
immunosensor on cHL patients. Our strategy shall focus on
the implementation of standard electrode architectures and
simple functionalization chemistries, which hold potential for
commercialization and rapid and economical testing with
printed electrodes (Figure 1). Only in doing so will clinical
translation become a reality, which would transform the patient
pathway and positively impact outcomes for cHL patients.
■ MATERIALS AND METHODS
Clinical Samples. Pre- and on-treatment cHL patient samples
were collected from two studies: Investigation of The Cause of
Hodgkin lymphoma (ITCH) and Biomarkers and classical Hodgkin
lymphoma (BACH). Samples represent serum CCL17/TARC levels
across cHL patients, which were quantified using the Human CCL17/
TARC Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis).
Healthy volunteer samples were collected from the Study of Healthy
Adult Response to EBV (SHARE). Fifty-four samples were tested: 5
healthy volunteers, 42 pre-, and 7 on-treatment cHL patients (details
in Table S1). All studies were approved by Research Ethics
Committees, and all participants gave written, informed consent.
Materials and Reagents. Concentrated sulfuric acid (98%),
hydrogen peroxide (30%) in water, and the CHI120 polishing kit
(CH Instruments, Inc., Austin) were purchased for electrode cleaning.
Sulfosuccinimidyl 6-(3′-(2-pyridyldithio)propionamido)hexanoate
(Sulfo-LC-SPDP), DL-dithiothreitol (DTT), 6-mercapto-1-hexanol
(MCH), tris(2-carboxyethyl)phosphine (TCEP), phosphate-buffered
saline (PBS), deionized (DI) water (Millipore, Livingston, West
Lothian), Human CCL17/TARC DuoSet ELISA (R&D Systems,
Inc., Minneapolis), and Amicon Ultra-0.5 mL 3 kDa filters were used
for immobilization. Potassium ferri/ferrocyanide and the DuoSet
ELISA Reagent kit 1 (R&D Systems) were purchased for testing.
Unless otherwise stated, reagents were purchased from Sigma-Aldrich
(Sigma-Aldrich, Poole, Dorset).
Instrumentation. Experiments were conducted on a PalmSens
Emstat potentiostat (PalmSens, The Netherlands) with one CH
Instruments CHI101 gold working, CHI111 silver silver/chloride
reference, and CHI115 platinum counter electrode.
Cleaning. Working electrodes were chemically, mechanically, and
electrochemically cleaned as documented in the Supporting
Information.
Immobilization. A sandwich CCL17/TARC antibody assay was
immobilized on working electrodes through modification of a
previous protocol.33,42 All details are provided in the Supporting
Information.
Amperometric experiments applied a potential of −0.2 V for 120 s
with 0.1 s time intervals. The time period produced the lowest
standard deviation for triplicate measurements compared to shorter
time periods. We hypothesize an extended time period ensures
sufficient time for the signal to fully permeate the dense SAM
antibody film. However, there may be scope to reduce this time
period in the future.
Assay Characterization. Electrochemical impedance spectrosco-
py (EIS) and cyclic voltammetry (CV) were performed to
characterize immobilization. Electrodes were immersed in 10 mM
ferri/ferro potassium cyanide in 1× PBS solution. EIS measurements
were recorded at open circuit potential (OCP) with an applied AC
potential of 10 mV rms amplitude over a 0.1−100 000 Hz range. The
measurement solution contained equal concentrations of potassium
ferri/ferrocyanide and, thus, a potential was fixed between the two
peaks of the redox couple. This made it possible to perform EIS
measurements at OCP with theoretically equal amounts of oxidized
and reduced species present before imposing the AC excitation signal.
This is an approach that has been used by ourselves,42,43 and many
others previously. CV experiments were conducted between −0.4 and
0.6 V with a step of 0.01 V at scan rates of 50 mV/s. All
measurements were performed on three functionalized working
electrodes.
Reproducibility Study. Please refer to the Supporting
Information for reproducibility study details on functionalized
working electrodes.
Statistics. EIS data was modeled with Randles equivalent circuit
and fitted with the Levenberg−Marquardt model to determine Rct at
working electrodes. Rct variability was quantified for immobilization
steps with probability distribution plots at 95% confidence intervals.
One-way analysis of variance (ANOVA) evaluated mass-transfer
limited currents at 120 s for all samples tested during spiked studies at
95% confidence intervals. The test permits equality testing between
two or more means and, thus, determines statistical significance
between spiked CCL17/TARC and control samples. Post-hoc Tukey
testing identified all statistically significant CCL17/TARC concen-
trations, where p-values < 0.05. Four-parameter logistic (4PL)
regression determined the relationship between logarithms of
CCL17/TARC concentration and current for statistically significant
concentrations, where p-values < 0.05. 4PL regression is used to
characterize nonlinear biological assays over wide concentration











where y is the response variable, A1 is the smallest response, A2 is the
greatest response, x0 is the inflection point, and p is the slope
parameter that defines curve steepness. Curve fitting used least
squares regression and assumed a normal data distribution. No
weighting was used as standard deviation was not proportional to
CCL17/TARC concentration.
One-way ANOVA studies were conducted on currents at 120 s for
pretreatment samples to determine statistical significance between
respective cHL and control patients at 95% confidence intervals. One-
way ANOVA also analyzed responses of patients categorized
according to known CCL17/TARC concentration: control (<1 ng/
mL), group A cHL (1−5 ng/mL), group B cHL (5−10 ng/mL),
group C cHL (10−50 ng/mL), and group D cHL (>50 ng/mL). This
allowed statistical testing to determine whether electrochemical
responses of patients were proportional to CCL17/TARC concen-
tration. Tukey testing identified all statistically significant groups,
where p-values < 0.05.
A paired t-test evaluated current responses at 120 s between all
paired pre- and on-treatment patient samples at 95% confidence
intervals. The paired t-test assumed the dependent variable was
continuous, approximately normally distributed, did not feature
outliers, and response measurements were independent. One-way
ANOVA then determined across all individual patients whether pre-
and on-treatment currents at 120 s were statistically significant at 95%
confidence intervals. Tukey testing identified all statistically significant
differences between groups where p < 0.05.
One-way ANOVA analyses assumed that the dependent variable
was continuous, approximately normally distributed, the variance was
approximately equal across groups, and responses were independent
observations. Tukey testing used identical assumptions and assumed
that responses were independent within and among groups. Tukey
testing performs all pairwise comparisons and was appropriate given a
large number of groups in our data while minimizing type I error.
The correlation between electrochemical and colorimetric ELISA
tests was established by plotting the logarithm of predicted serum
CCL17/TARC concentration for all patients. Linear regression
determined the relationship between tests, and Pearson’s r coefficient
specified the magnitude of the relationship. Linear regression assumed
linearity, the dependent variable was normally distributed, variance of
error was constant, and observations were independent.
■ RESULTS AND DISCUSSION
Electrochemical Characterization. Working electrodes
were electrochemically cleaned (Figure S1) prior to immobi-
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lization to improve chemisorption between the cross-linker and
gold. EIS and CV experiments determined electrode
cleanliness (Figure 2). Bare working electrodes measured
small charge-transfer resistances, Rct = 107 ± 11.5 Ω, which
indicates that the redox couple can freely participate in
electron-transfer events, and implies that electrodes are
appropriately clean. Working electrodes immobilized with
primary CCL17/TARC antibodies conjugated to Sulfo-LC-
SPDP measured a marked increase in Rct = 2.173 × 10
4 ± 2.32
× 103 Ω, which suggests [Fe(CN)6]−3/4 ions have reduced
ability to participate in electron transfer due to antibody SAM
formation. Working electrodes functionalized with MCH
measured a marked increase in Rct = 2.95 × 10
4 ± 3.02 ×
103, indicative of chemisorption of MCH to gold. Variation in
Rct was consistent across respective assay depositions, with a
CV of 10.7% for the cross-linked CCL17/TARC antibody
layer and 10.3% for the MCH layer, compared to 10.8% for
bare electrodes. Hence, assay immobilization did not
negatively influence measurement variation. Probability
distribution plots quantified Rct variability for all immobiliza-
tion steps (Figure S2). Reassuringly, Rct values were within
95% confidence intervals for all immobilization steps,
indicative of reproducible SAM formation. Probability
distributions and CV values may be employed as future quality
control measures to ensure SAM formation gives rise to
acceptable variation in Rct at working electrodes. Additionally,
a one-sample t-test should be employed to quantify SAM
variation by comparing the population mean of Rct for
respective assay depositions to the hypothesized mean stated
above.
Bare working electrodes measured Ipa/Ipc values close to
unity, characteristic of a reversible redox reaction, and was
anticipated for Fe(CN)6
−3/4 species as it is a well-established
reversible redox couple. Electrodes functionalized with
CCL17/TARC antibodies measured decreases in Ipa and Ipc,
which indicates that the dense protein layer hinders electron
transfer of [Fe(CN)6]
−3/4 ions at electrode surfaces. Electrodes
immobilized with MCH observed decreases in Ipa and Ipc,
which suggests thiol attachment further restricts electron-
transfer events. Working electrodes recorded consecutive
increases in ΔEp following assay depositions, from ΔEp =
0.110 V to ΔEp = 0.809 V. ΔEp, referred to as peak-to-peak
separation, is defined as the separation between anodic and
cathodic peak potentials. ΔEp is used to determine electro-
chemical reversibility and describes the rate of electron transfer
between the working electrode and analyte. Electrochemically
reversible reactions have a low thermodynamic barrier to
electron transfer, resulting in a fast rate of electron transfer.
Theoretically, electrochemical reversibility occurs when ΔEp =
57 mV for a one-electron transfer reaction at 25 °C; however,
ΔEp is typically higher during experimentation. Electrochemi-
cally irreversible reactions have a high thermodynamic barrier
to electron transfer with a slow rate of electron transfer.
Consequently, one must supply greater positive and negative
potentials to initiate oxidation and reduction reactions,
respectively, resulting in a greater ΔEp. Hence, increases in
ΔEp for assay depositions indicate slow electron-transfer
kinetics due to successful immobilization to working electro-
des.
Assay reproducibility was evaluated over a 7 day period to
determine SAM variability between electrodes and assay
batches (Figure S3). Primary antibody immobilization
increased Rct signals at working electrodes on respective
days. However, Rct varied between working electrodes each
day, with an interassay coefficient of variation (CV) of 21.7%
over a 7 day period. Working electrodes also recorded variation
in Rct on different days, indicative of inconsistent antibody
immobilization between assay batches. Working electrodes
observed increases in Rct following backfilling procedures on
respective days. However, Rct signals varied between working
electrodes each day, with an interassay CV of 20.0% over the 7
day period, highlighting variation in MCH immobilization.
Working electrodes also recorded variation in Rct on different
days, suggestive of inconsistent MCH immobilization between
assay batches. Thiol SAM formation on gold occurs in a two-
step process, a fast and slow growth phase, where the density
and packing of molecules is influenced by several external and
internal factors. The fast growth phase is influenced by surface
cleanliness, concentration of adsorption molecules, immersion
time, temperature, and humidity.44,45 Fluctuations in exper-
imental conditions may likely explain Rct variability between
days. The slow growth phase partly determines SAM
Figure 2. (a) Nyquist and (b) CV plot for one functionalized electrode following respective assay depositions.
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morphology and is influenced by hydrogen bonding and van
der Waals forces between alkane thiol chains.46 Thus, SAM
stability and density may be improved by selecting alkane
thiols of increased chain length. Nevertheless, current findings
indicate successful assay immobilization.
Electrochemical Detection of TMB Oxidation States.
Electrodes were immersed in substrate solution and subjected
to CV to determine the redox potentials of TMB products. In
sandwich assays that utilize horseradish peroxidase, the enzyme
catalyzes the reduction of hydrogen peroxide to water in the
presence of the native TMB diamine that acts as a proton
donor.47 Consequently, TMB is subjected to a one-electron
transfer oxidation reaction. The oxidized TMB product can be
detected electrochemically at Epa = 0.06 V (Figure 3a). The
TMB product often undergoes a second oxidation reaction in
the presence of sulfuric acid and can be detected electro-
chemically at Epa = 0.21 V. The TMB products gain one
electron during subsequent reduction reactions, which were
observed at Epc = 0.17 V and Epc = 0.01 V, respectively. Hence,
electrodes identified redox reaction characteristic of electro-
chemical TMB detection.48 The oxidized product is propor-
tional to antigen concentration and can be measured
electrochemically by reducing oxidized species with an
appropriate Epc. A potential of Epc = −0.20 V was selected
for amperometric experiments as the potential does not
coincide with oxidation potentials, Epa, of TMB.
Concentration Study for CCL17 Antigen Detection.
Amperometric curves showed a reduction of oxidized TMB
species, where consumption of reactants with time produced a
constant concentration gradient and mass-transfer limited
currents (Figure 3b). Immunosensors showed significant
discrimination between control and sample mass-transfer
limited currents at 120 s for spiked CCL17/TARC
concentrations ≥194 pg/mL (p-value < 0.05) (Figure 3c).
Figure 3. (a) CV plot of electrochemical characterization of TMB. (b) Amperometry plot of spiked CCL17/TARC samples (0−50 000 pg/mL) (n
= 3). (c) Plot of currents at 120 s for spiked CCL17/TARC samples (n = 3). Asterisks indicate statistical significance, where p < 0.05. (d)
Calibration curve of the logarithm of CCL17/TARC concentration and logarithm of statistically significant currents at 120 s, where p < 0.05 (n =





, and best fit values were calculated as A1 = −1.482, A2 = 1.889 × 10−2,
log x0 = 2.863, and p = 0.4816.
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Signals were not linear over the specified concentration range,
which is unsurprising given the wide concentration range.
Mass-transfer limited currents at 120 s displayed a strong
positive relationship with CCL17/TARC concentration, R2 =
0.986, for concentrations statistically different from control
measurements (p-value < 0.05) (Figure 3d). 4PL regression
was suitable for analysis as the model has been employed in
electrochemical immunoassays49 and better represents bio-
logical systems that display nonlinear behavior over wide
concentration ranges. Interassay CV for mass-transfer limited
currents at 120 s was 14.6% for all spiked CCL17/TARC
concentrations (24−50 000 pg/mL). Additionally, interassay
CV for mass-transfer limited currents at 120 s was 12.6% for
CCL17/TARC concentrations (194−50 000 pg/mL) statisti-
cally significant from control samples (p-value < 0.05). Lower
and upper limits of quantitation were 387 and 50 000 pg/mL,
respectively (based on CV ≤20%), with a limit of detection of
194 pg/mL.
Comparatively, the biosensor demonstrates a superior
dynamic range, with an upper limit of quantitation of 50 000
pg/mL CCL17/TARC compared to 2000 pg/mL for the
equivalent colorimetric ELISA platform. The biosensor
demonstrates reduced test sensitivity at 194 pg/mL when
compared to the equivalent colorimetric ELISA test at 7 pg/
mL.
Nevertheless, test sensitivity is well below the proposed
clinical cutoff for CCL17/TARC in cHL patients at 1000 pg/
mL50 and therefore shows significant promise for clinical
testing. However, the test showed reduced precision to
quantify CCL17/TARC around the clinical cutoff, with
unexpectedly raised signals for 775 pg/mL CCL17/TARC.
Therefore, test precision and accuracy must improve during
future assay development for patients that have CCL17/TARC
concentrations near the clinical cutoff, although preliminary
findings are extremely encouraging for clinical testing.
Detection of CCL17/TARC in Pretreatment Patient
Serum Samples. Electrochemical immunosensors measured
significant increases in currents at 120 s for all 42 cHL patients
relative to healthy volunteers (p-value < 0.05) (Figure 4a,b).
Interassay CV of 19.5% across all patients was greater than
previous concentration studies, likely attributable to the
complexity of biologically rich serum derivatives. Nevertheless,
the biosensor demonstrates the capacity to discriminate
between healthy volunteers and cHL patients that have raised
CCL17/TARC levels, which reflects ∼90% of all cHL
patients.1,7 Electrode responses were significantly different
between healthy volunteers and all cHL patient groups (p-
value < 0.05), stratified according to known CCL17/TARC
concentrations (Figure 4c). Hence, the biosensor has the
potential to quantify serum CCL17/TARC in cHL patients,
which is important clinically as CCL17/TARC correlates with
tumor burden.3−8 However, further testing must be conducted
on cHL patients with known CCL17/TARC levels at the
Figure 4. (a) Amperometric curves for functionalized electrodes following incubation with patient serum samples (n = 3). (b) Electrode current
responses at 120 s following incubation with patient serum samples (n = 3). (c) Electrode current responses categorized into patient groups, based
on known CCL17/TARC concentration; group A (1−5 ng/mL), group B (5−10 ng/mL), group C (10−50 ng/mL), and group D (>50 ng/mL).
Asterisks indicate statistical significance, where p < 0.05; cHL denotes classic Hodgkin lymphoma.
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Figure 5. (a) Amperometric curves for paired patient serum samples tested at pretreatment and on-treatment clinical stages (n = 3). (b) Plot of
electrode current responses at 120 s for clinical patient serum samples (n = 3).
Figure 6. (a) Plot of biosensor and ELISA test predictions for CCL17/TARC in pretreatment patients. (b) Correlation of predicted CCL17/
TARC in pretreatment patients between the biosensor and ELISA tests. (c) Plot of the biosensor and ELISA test predictions for CCL17/TARC in
pretreatment (PT) and on-treatment (OT) patient samples. (d) Correlation of predicted CCL17/TARC in pretreatment (PT) and on-treatment
(OT) patient samples between the biosensor and ELISA tests.
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clinical cutoff to confirm that the test identifies all cHL
patients.
To the best of our knowledge, our findings demonstrate, for
the first time, sensitive electrochemical detection of serum
CCL17/TARC from pretreatment cHL patients. Electro-
chemical detection of CCL17/TARC has potential for rapid,
economical point-of-care triage testing of cHL patients,
following further assay optimization and utilization of printed
electrodes. Clinically, the test would provide a minimally
invasive and highly accessible platform to promote early
detection of cHL and enable timely referral for diagnosis with
lymph node biopsy. Practically, discriminatory signals can be
generated in seconds to minutes and require minimal user
interpretation, which offers the potential to streamline the
diagnostic pathway. Economically, electrochemical biosensors
offer a scalable technology with the adoption of printed
electrodes, which would minimize test costs for healthcare.
Presently, time-to-result from sample introduction is 2 h 42
min; thus, reduction in assay time is required to enable while-
you-wait results. Strategies to streamline the test toward point-
of-care include a reduction in or elimination of wash steps and
reduction in assay incubation times. Incubation temperature,
pH, and ionic strength of solutions should also be carefully
considered, as these factors influence the equilibrium constant
of antigen−antibody reactions. Secondary antibody concen-
tration should also be optimized, as this influences the law of
mass action governing antibody−antigen reactions. Direct
conjugation of horseradish peroxidase to secondary antibodies
prior to immobilization would further reduce time-to-result.
Practically, whole blood testing should be considered to
determine whether upfront sample processing can be
eliminated. The development of instrumentation that integra-
tes with the biosensor to enable automation of assay
procedures should be strongly considered to streamline clinical
workflows.
Biosensor reproducibility must be improved for clinical
testing, given the current interassay CV of 19.5% for patient
samples. Interassay CV ≤15% is acceptable for bioanalytical
tests, although ≤20% is deemed acceptable for measurements
approaching the lower limit of quantitation.51−53 Test
variability is likely attributable to variable SAM formation,
detailed in reproducibility studies. Electrode topography is also
likely partly responsible for the signal variation. SEM revealed a
degree of surface roughness with small scratches on electrodes
due to repeated mechanical polishing54 (Figure S4). AFM
confirmed superficial electrode scratches, although substrates
were relatively smooth with good surface homogeneity (Figure
S5). These observations are reassuring as high surface
roughness promotes poor thiol organization and hinders
SAM formation.55,56 Furthermore, intra-assay CV for 23
patient samples was ≤15%, providing evidence the biosensor
has potential for clinical testing.
Evaluating Treatment Response through Serum
CCL17/TARC Detection. Testing was performed on cHL
patient serum obtained pre- and on-treatment to determine
biosensor utility for treatment response monitoring. Immuno-
sensors measured significant decreases in current at 120 s
between pre- and on-treatment groups (p-value < 0.05), and
for all paired cHL patient samples (p-value < 0.05) (Figure
5a,b). Thus, the biosensor has the potential for monitoring
treatment response, provided CCL17/TARC is clinically
utilized in the future. Recently, decreases in CCL17/TARC
in cHL patients have been shown to inform treatment response
after one chemotherapy cycle,5,25 which would facilitate earlier
identification of refractory patients, and address false-positive/
negative results associated with interim PET/CT.8,23,24
Likewise, CCL17/TARC has clinical potential to identify HL
patients unresponsive to allogeneic stem cell transplants.5,7,57
Thus, the biosensor represents a promising tool as an adjunct
or alternative to interim PET-CT, with the potential to support
development of personalized treatment strategies.
Comparison of Electrochemical Immunosensor with
CCL17/TARC ELISA Platform. The concentration of serum
CCL17/TARC determined using the electrochemical bio-
sensor was significantly lower than the Human Quantikine
CCL17/TARC colorimetric ELISA test (p-value < 0.05)
(Figure 6a). The biosensor underestimated CCL17/TARC in
33/42 patient samples and was particularly evident for patients
with very high CCL17/TARC levels. Optimization of sample
dilution should be considered to address poor test perform-
ance for patients with high CCL17/TARC levels. Nevertheless,
biosensor quantification of CCL17/TARC in pretreatment
patients positively correlated (Pearson’s r = 0.910) with the
ELISA test (Figure 6b). The biosensor also underestimated
serum CCL17/TARC for pre- and on-treatment cHL samples
compared to the ELISA test (Figure 6c). However, measure-
ments still positively correlated (Pearson’s r = 0.880) with the
ELISA test (Figure 6d). The biosensor was unable to estimate
serum CCL17/TARC for three healthy volunteers and five
cHL patients during chemotherapy, which were all quantified
by ELISA. Signals for these patients were below the lower
interpolation limit of the calibration curve, and thus it was not
possible to accurately quantify CCL17/TARC concentrations.
However, serum CCL17/TARC concentration in these
samples was in the low normal range, well below the proposed
clinical cutoff for raised CCL17/TARC, and therefore would
not affect the clinical usefulness of the assay.
Analytical discrepancies between the biosensor and ELISA
test may be attributed to reduced sample volumes at 25 μL for
electrodes compared to 100 μL for ELISA plates. Substrate
solution volumes may contribute to analytical errors; 500 μL is
used for electrochemical tests compared to 100 μL for ELISA,
which may dilute signals. Primary antibody concentrations
were greater for the biosensor and may introduce analytical
error, since excessive concentrations can negatively influence
antibody−antigen affinity through steric hindrance.58 Thus,
primary antibody titration experiments and a thorough
evaluation of the assay protocol must be conducted in future
studies to realize the clinical potential of the biosensor.
■ CONCLUSIONS
The need for earlier diagnosis of cHL is well recognized and
forms part of a wider key healthcare strategy to detect 75% of
all cancers at an early stage in the U.K. by 2028.59 An
electrochemical biosensor for serum CCL17/TARC detection
has the potential to facilitate triage of patients who have a
differential diagnosis that includes cHL in primary care and has
the potential to permit monitoring of chemotherapy response
in secondary care. The electrochemical biosensor has
demonstrated quantitative detection of CCL17/TARC with
high sensitivity, linearity, and a large dynamic range (387−
50 000 pg/mL). The biosensor demonstrated successful
discrimination between serum samples of all cHL patients
and healthy volunteers, which shows considerable promise for
clinical translation of a point-of-care triage strategy. Addition-
ally, the biosensor showed the ability to qualitatively measure
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decreases in serum CCL17/TARC between all seven paired
pre- and on-treatment cHL patient samples, which provides
the potential to measure treatment response during chemo-
therapy. Overall, our preliminary findings have demonstrated
considerable potential for electrochemical detection of serum
CCL17/TARC in clinical samples and represent an important
step toward the development of a rapid triage and treatment
response test for cHL.
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